ELASTATHERAPY
Live / Applied — Second extension granted (statement of use) (as of 04 Feb 2026)
What this means for you
Not registered yet, but its 05 Feb 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98391875
- Mark type
- Stylized text
- Filed
- 05 Feb 2024
- Published for opposition
- 10 Dec 2024
- Attorney of record
- Cheryl A. Withycombe
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and compositions for the treatment of acquired and congenital skin conditions and acquired and congenital skin diseases; biochemical and biological substances for medical use, namely, forms of protein and polysaccharide preparations for the treatment of acquired and congenital skin conditions and acquired and congenital skin diseases; drug delivery preparations for medical use, namely, forms of protein and polysaccharide preparations used for the controlled release of pharmaceuticals; medical preparations, namely, medicated skin care preparations
Owner
- Allergan Pharmaceuticals International Limited, Dublin 17, IE
- Allergan Pharmaceuticals International Limited, Dublin 17, IE
Prosecution history
- 04 Feb 2026 — SOU EXTENSION 2 GRANTED
- 04 Feb 2026 — SOU EXTENSION 2 FILED
- 04 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 05 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Aug 2025 — SOU EXTENSION 1 GRANTED
- 04 Aug 2025 — SOU EXTENSION 1 FILED
- 04 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Feb 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 10 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Dec 2024 — PUBLISHED FOR OPPOSITION
- 04 Dec 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Nov 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 11 Nov 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 11 Nov 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED